MLL-rearrangement is an independent poorer prognostic factor in both ALL and AML [31], but the most common MLL/AF9 mutation in AML only indicates an intermediate prognosis [30,32]. This evidence concerns the gene KMT2A and acute lymphoblastic leukemia.